Jeremy Katzen1, Rachel Kohn1, Jessica L Houk2, Michael G Ison3. 1. Division of Pulmonary and Critical Care Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. 2. Division of Radiology, Duke University, Durham, North Carolina. 3. Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
BACKGROUND: Neuraminidase inhibitors (NAIs) are the only effective therapy for influenza, but few studies have assessed the impact of early NAI therapy on clinical outcomes or the patient-level factors that determine early NAI delivery in hospitalized patients. METHODS: We conducted a retrospective cohort study of all adults hospitalized in a metropolitan tertiary care hospital with confirmed influenza from April 2009 to March 2014. We performed logistic regression to determine patient-level factors that were associated with early NAI therapy. We analyzed the association of early NAI therapy with hospital lengths of stay (LOS) and in-hospital mortality rates using linear and logistic regression, respectively. RESULTS: In total, 699 patients were admitted with influenza during the 5 influenza seasons. Of those, 582 (83.4%) received NAI therapy; however, only 26.0% received the first dose within 6 hours of hospitalization (early NAI). Patients with diabetes mellitus or pregnancy were more likely to receive early NAI (P = .01, vs. P < .001 in those without these conditions), as were those reporting fever or myalgias at presentation (P = .002, vs. P = .005 without). Immunosuppressed patients were less likely to receive early NAI (P = .04). Early NAI was associated with shorter hospital LOS (P < .001). No patients died in the early NAI group, compared to 18 deaths in the 399 patients receiving NAI after 6 hours (4.5%) and 4 deaths in the 116 patients not receiving NAI (3.4%). CONCLUSIONS: Over multiple influenza seasons, early NAI therapy was associated with shorter LOS in patients admitted with influenza. This suggests that efforts should focus on facilitating earlier therapy in patients with suspected influenza.
BACKGROUND: Neuraminidase inhibitors (NAIs) are the only effective therapy for influenza, but few studies have assessed the impact of early NAI therapy on clinical outcomes or the patient-level factors that determine early NAI delivery in hospitalized patients. METHODS: We conducted a retrospective cohort study of all adults hospitalized in a metropolitan tertiary care hospital with confirmed influenza from April 2009 to March 2014. We performed logistic regression to determine patient-level factors that were associated with early NAI therapy. We analyzed the association of early NAI therapy with hospital lengths of stay (LOS) and in-hospital mortality rates using linear and logistic regression, respectively. RESULTS: In total, 699 patients were admitted with influenza during the 5 influenza seasons. Of those, 582 (83.4%) received NAI therapy; however, only 26.0% received the first dose within 6 hours of hospitalization (early NAI). Patients with diabetes mellitus or pregnancy were more likely to receive early NAI (P = .01, vs. P < .001 in those without these conditions), as were those reporting fever or myalgias at presentation (P = .002, vs. P = .005 without). Immunosuppressed patients were less likely to receive early NAI (P = .04). Early NAI was associated with shorter hospital LOS (P < .001). No patients died in the early NAI group, compared to 18 deaths in the 399 patients receiving NAI after 6 hours (4.5%) and 4 deaths in the 116 patients not receiving NAI (3.4%). CONCLUSIONS: Over multiple influenza seasons, early NAI therapy was associated with shorter LOS in patients admitted with influenza. This suggests that efforts should focus on facilitating earlier therapy in patients with suspected influenza.
Authors: Mario Karolyi; Erich Pawelka; Hasan Kelani; Georg Christian Funk; Boris Lindner; Christoph Porpaczy; Sabine Publig; Sara Omid; Tamara Seitz; Marianna Traugott; Michael Turner; Alexander Zoufaly; Christoph Wenisch Journal: Wien Klin Wochenschr Date: 2021-10-06 Impact factor: 1.704
Authors: Carol M Kao; Kristina Lai; John M McAteer; Mohnd Elmontser; Elizabeth M Quincer; Marianne E M Yee; Ashley Tippet; Robert C Jerris; Peter A Lane; Evan J Anderson; Nitya Bakshi; Inci Yildirim Journal: Pediatr Blood Cancer Date: 2020-05-29 Impact factor: 3.167
Authors: Mario Karolyi; E Pawelka; H Kelani; G C Funk; B Lindner; C Porpaczy; S Publig; T Seitz; M Traugott; M Unterweger; A Zoufaly; C Wenisch Journal: Infection Date: 2020-10-22 Impact factor: 3.553
Authors: James C King; John H Beigel; Michael G Ison; Richard E Rothman; Timothy M Uyeki; Robert E Walker; James D Neaton; John S Tegeris; James A Zhou; Kimberly L Armstrong; Wendy Carter; Peter S Miele; Melissa S Willis; Andrea F Dugas; LaRee A Tracy; David M Vock; Rick A Bright Journal: Open Forum Infect Dis Date: 2019-03-14 Impact factor: 3.835
Authors: M Bassetti; D R Giacobbe; S Aliberti; E Barisione; S Centanni; F G De Rosa; F Di Marco; A Gori; G Granata; M Mikulska; N Petrosillo; L Richeldi; P Santus; C Tascini; A Vena; P Viale; F Blasi Journal: Clin Microbiol Infect Date: 2020-04-29 Impact factor: 8.067
Authors: Mario Karolyi; Erich Pawelka; Theresa Mader; Sara Omid; Hasan Kelani; Sarah Ely; Bernd Jilma; Sebastian Baumgartner; Hermann Laferl; Clemens Ott; Marianna Traugott; Michael Turner; Tamara Seitz; Christoph Wenisch; Alexander Zoufaly Journal: Wien Klin Wochenschr Date: 2020-08-10 Impact factor: 2.275